Efficacy of tyrosine kinase inhibitors in patients with non-small-cell lung cancer with performance status 4: a case series and review of the literature

BACKGROUND: Current guidelines for non-small-cell lung cancer (NSCLC) recommend that each tyrosine kinase inhibitor (TKI) is indicated even for driver mutation-positive patients with a poor performance status (PS). In previous studies, most patients had a PS of 2–3, but those with a PS of 4 were ver...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Akinori, Fujimoto, Yutaro, Inada, Takashi, Ishizuka, Azusa, Ehara, Jun, Ogita, Shin, Norisue, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538240/
https://www.ncbi.nlm.nih.gov/pubmed/37759318
http://dx.doi.org/10.1186/s13256-023-04145-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538240/
https://www.ncbi.nlm.nih.gov/pubmed/37759318
http://dx.doi.org/10.1186/s13256-023-04145-z

Ejemplares similares